IP Library Granted Patent US 9,422,352
Granted Patent B2
US 9,422,352 · App. 14/201,488 · Granted Aug 23, 2016

PTD-SMAD7 therapeutics

Inventors: Xiao-Jing Wang (Greenwood Village, CO); Qinghong Zhang (Englewood, CO); Yosef Refaeli (Denver, CO)
Assignee: The Regents of the University of Colorado, a body corporate
C07K14/4703C07K14/4702A61K38/00A61K48/005C07K2319/10C07K2319/20C07K2319/23C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,422,352
App. No.
14/201,488
Granted
Aug 23, 2016
Kind
B2
Abstract

The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Claims (11)

1. A protein comprising a functional Smad7 domain, wherein the functional Smad7 domain consists of the amino acid sequence as set forth in SEQ ID NO: 12 with a Met216Leu substitution, and wherein the protein antagonizes TGF-β signaling comparable to wild-type Smad7.

2. The protein of claim 1 , further comprising a protein transduction domain.

3. The protein of claim 2 , wherein the protein transduction domain is a variant of TAT protein from HIV or HSV VP16.

4. The protein of claim 1 , further comprising one or more of an epitope tag or a purification tag.

5. A protein comprising a functional Smad7 domain, wherein the functional Smad7 domain consists of amino acids 2 to 258 of the amino acid sequence as set forth in SEQ ID NO: 12 with a Met216Leu substitution.

6. The protein of claim 5 , further comprising a protein transduction domain.

7. The protein of claim 6 , wherein the protein transduction domain is a variant of TAT protein from HIV or HSV VP16.

8. The protein of claim 5 , further comprising one or more of an epitope tag or a purification tag.

9. The protein of claim 5 , wherein the functional Smad7 domain has one or more biological activities selected from the group consisting of mediating cell migration, promoting cell proliferation, reducing radiation-induced DNA damage, and blocking fibrotic response.

10. A method for preventing or treating a disease or disorder in a subject comprising one or more of increasing one or more of cell proliferation or cell migration, or preventing one or more of apoptosis or DNA damage in the subject comprising providing to the subject a therapeutically effective amount of a pharmaceutical composition comprising the protein molecule of claim 1 , wherein one or more of increasing one or more of cell proliferation or cell migration, or preventing one or more of apoptosis or DNA damage is useful in preventing or treating the disease or disorder.

11. The method of claim 10 , wherein the disease or disorder includes one or more of chronic wounds, acute wounds, or mucositis.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 18, 2018
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047101/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2016
From: WANG, XIAO-JING; ZHANG, QINGHONG; REFAELI, YOSEF
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 038530/0074 →
Continuity (2)
Provisional Application 61775252 · Mar 8, 2013
Related Publication 20140288006A1 · Sep 25, 2014